The DIAN Trials Unit (DIAN-TU) platform implements interventional therapeutic trials for at-risk families with DIAD, focusing on drugs that can potentially change the course of the disease. DIAN-TU enrolls in two types of trials: primary prevention trials and secondary prevention trials.
Clinical drug trials are available for individuals who have or are at risk for dominantly inherited Alzheimer’s disease.
DIAN-TU trials
Primary Prevention Trial
DIAN-TU-002
The evidence is clear that amyloid beta (Aβ) accumulates in the brain years before dementia symptoms first appear.
These trials seek to intervene before amyloid plaques form in the brain.
Secondary Prevention Trials
DIAN-TU-001, DIAN-TU-003
Prevention efforts target amyloid beta (Aβ) in individuals after amyloid plaques are present in the brain.
These trials seek to intervene in the disease process before too much permanent damage is done.
The DIAN-TU site staff will determine which study is best suited for each potential participant, based on their estimated years to (symptom) onset, or “EYO”. A person’s EYO takes into consideration the actual age of the participant and the age at which their parent or relative became symptomatic.